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Abstract
The aim of this study was to evaluate the in vitro activity of the synthetic peptide hLF1-11
against biofilm produced by clinical isolates of Candida albicans with different fluconazole
susceptibility. The antibiofilm activity of the peptide hLF1-11 was assessed in terms of
reduction of biofilm cellular density, metabolic activity and sessile cell viability. The extent of
morphogenesis in hLF1-11 treated and untreated biofilms was also investigated microscopi-
cally. Transcription levels of genes related to cell adhesion, hyphal development and extra-
cellular matrix production were analysed by qRT-PCR in hLF1-11 treated and untreated
biofilms. Exogenous dibutyryl-cAMP (db-cAMP) was used to rescue morphogenesis in cells
exposed to the peptide. The results revealed that hLF1-11 exhibited an inhibitory effect on
biofilm formation by all C. albicans isolates tested in a dose-dependent manner, regardless
of their fluconazole susceptibility. Visual inspection of treated or untreated biofilm cells with
an inverted microscope revealed a significant reduction in hyphal formation by hLF1-11
treated cells, as early as 3 hours of incubation. Moreover, hLF1-11 showed a reduced activ-
ity on preadherent cells. hLF1-11 induced the down-regulation of biofilm and hyphal-associ-
ated genes, which were predominantly regulated via the Ras1-cAMP-Efg1 pathway.
Indeed, exogenous db-cAMP restored morphogenesis in hLF1-11 treated cells. The hLF1-
11 peptide significantly inhibited biofilm formation by C. albicans mainly at early stages,
interfering with biofilm cellular density and metabolic activity, and affected morphogenesis
through the Ras1-cAMP-Efg1 pathway. Our findings provide the first evidence that hLF1-11
could represent a potential candidate for the prevention of biofilm formation by C. albicans.
Introduction
Candida albicans is an opportunistic yeast, responsible for systemic infections in individuals
with impaired immune response [1]. Nosocomial C. albicans infections are often related to the
ability to produce biofilm on mucosal surfaces and implanted medical devices [2–4]. Biofilm
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formation is a finely regulated process, which involves multiple interconnected signalling path-
ways [5], leading to a structured microbial community that is attached to a surface and embed-
ded in an exopolymeric extracellular matrix [2,6,7]. The polysaccharide matrix acts as a barrier
for sessile cells, preventing the entrance of most commonly used antifungal agents, thus con-
ferring drug resistance. Indeed, sessile C. albicans cells are up to 1000-fold more resistant to
common antifungals than planktonic cells, even in the absence of specific drug-resistance
genes [8,9]. Thereby, biofilm is a reservoir of viable fungal cells potentially leading to systemic
infections, with a mortality rate of 40–60% [10,11].
Increasing efforts are currently underway in developing alternative strategies aimed at erad-
icating biofilm-related infections. Among these, antimicrobial peptides (AMPs) have been
widely investigated as novel therapeutic agents [12,13].
Human lactoferrin (hLF) is an iron-binding glycoprotein (77 kDa) synthesized by mucosal
gland epithelial cells and neutrophils in response to inflammatory stimuli [14]. By pepsinolysis,
hLF releases lactoferricin H (residues 1 to 47) from its N-terminus, which contains two cat-
ionic domains (residues 2–5 and 28–31) [15,16]. A synthetic peptide comprising the first cat-
ionic domain of lactoferricin H, further referred to as hLF1-11, possesses a high antibacterial
and antifungal activity, with a more pronounced effect in vivo [17,18]. Furthermore, hLF1-11
exerts modulatory effects on immune cells stimulating macrophages and dendritic cells, thus
contributing to the clearance of infections [19,20]. In addition, previous studies have shown
that hLF1-11 has no cytotoxic effects against human erythrocytes, and its administration to
healthy volunteers was well tolerated [21].
Until now, the exact mechanisms of action of hLF1-11 are not fully characterised, despite
mitochondria seem to be a target of hLF1-11 in C. albicans [22].
To date, no evidence is available on the role played by the hLF1-11 peptide on biofilm pro-
duction by C. albicans, although immobilizing hLF1-11 onto titanium surfaces of implants
reduced bacterial adhesion and biofilm formation [23].
This study was aimed at i) evaluating the potential inhibitory activity of hLF1-11 against
biofilm formation of clinical isolates of C. albicans characterised by different fluconazole sus-
ceptibility, and ii) improving our understanding of the mechanism(s) underlying the hLF1-
11-induced antibiofilm activity.
Materials and Methods
Strains
A panel of Candida albicans strains including ten clinical isolates collected at the U. O. Micro-
biologia Universitaria, Azienda Ospedaliero-Universitaria Pisana (Pisa, Italy) and the refer-
ence strain SC5314 were investigated for biofilm production. Furthermore, fluconazole
susceptibility was determined by Vitek 2 system (AST-YS07 card; bioMe´rieux, Marcy l’E´toile,
France). All strains were stored in YPD broth (Yeast Peptone Dextrose, Difco BD, Milan,
Italy) supplemented with 40% (vol/vol) glycerol at -20˚C and -80˚C, subcultured at 37˚C on
YPD agar plates, and kept at 4˚C until testing. After 16h incubation at 30˚C, cells were washed
in sodium phosphate buffer (NaPB, pH 7) and suspended at the desired concentration.
Lactoferrin peptide
The synthetic peptide corresponding to the first eleven residues of human lactoferrin
(GRRRRSVQWCA; molecular mass, 1374.6 Da), further referred to as hLF1-11, was purified
by Peptisyntha Inc (Torrance, CA, USA), with purity exceeding 95%. Stocks (10mM in 0.01%
acetic acid; pH 3.7) were stored at -20˚C.
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hLF1-11-induced candidacidal activity on planktonic cells
The hLF1-11 antifungal activity was tested by the broth microdilution method according to
CLSI standard M27-A3 with minor modifications [24]. Briefly, a final suspension of 1×103
cells/ml in RPMI 1640 medium (diluted 1:4 in NaPB) was adjusted to pH 7 with 0.165 3-(N-
morpholino)-propanesulfonic acid (MOPS; Sigma Aldrich, St. Louis, USA) and inoculated in
polystyrene, round-bottomed, 96-well microtiter plates (Falcon, Becton Dickinson BD, Milan,
Italy) to reach a final volume of 100μl/well. hLF1-11 concentrations tested were 0.17-176mg/L.
Following incubation at 37˚C for 24h, MIC values were determined as the lowest peptide con-
centration inhibiting fungal growth. Two sets of independent experiments were performed,
each in duplicate.
Inhibition of biofilm formation
Fungal suspensions were prepared at 2×106 cells/ml in four-fold diluted RPMI 1640 medium
supplemented with glucose (2% final concentration) and buffered with MOPS. An aliquot of
each yeast suspension was transferred in polystyrene, flat-bottomed, 96-well microtiter plates
and incubated with different hLF1-11 concentrations (44, 88, 176mg/L) at 37˚C for 24h, in a
final volume of 100μl/well. The inhibitory activity of hLF1-11 on C. albicans biofilm formation
was also evaluated at earlier time points, including 1.5h, 3h, 6h and, as control, 24h, using a
peptide concentration of 88mg/L. A positive and negative control were included in each
experiment.
After incubation, non-adhered cells were removed by washing twice with phosphate buff-
ered saline (PBS). The antibiofilm activity of hLF1-11 was evaluated by i) spectrophotometri-
cally measuring the biofilm cellular density; (ii) quantifying metabolic activity by XTT assay,
and (iii) counting viable sessile cells (CFU/ml) after biofilm scraping from wells. Three inde-
pendent experiments were performed, each in triplicate.
Biofilm cellular density
Biofilm cellular density formed in the presence or absence of the peptide was determined by
measuring the optical density at 490 nm (ODλ490nm) using an automated plate reader (Model
550 Microplate Reader Bio-Rad, Milan Italy). Background optical density was subtracted from
the values measured in each well.
XTT assay
XTT solution was prepared at 0.5g/L in PBS buffer and mixed with a menadione solution dis-
solved in acetone at a final concentration of 1μM. An aliquot of 100μl of this solution was inoc-
ulated into each well containing dry preformed biofilms and the 96-well plate was incubated in
the dark at 37˚C for 2h. Next, the supernatant (80μL) was transferred into a 96-well plate to
measure colorimetric changes at 490 nm (Model 550 Microplate Reader).
Sessile cell viability
The recovery of sessile cells from biofilm formed on the well bottom was next evaluated.
Briefly, after washings, 200μl of PBS was added to the wells and adhered cells were detached by
scraping with the micropipette tip. Recovered cells were transferred to tubes containing 800μl
of PBS and vortexed for 5 minutes. Suspensions were then sonicated (VWR Ultrasonic Clea-
near, 230V/50-60Hz), vortexed, and serially diluted. Aliquots (200μl) of each dilution were
plated on YPD agar and colony counts were performed after 24h incubation at 37˚C.
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hLF1-11 activity on C. albicans cell morphology
In order to assess the hLF1-11-induced effect on the architecture of biofilm formed by C. albi-
cans, biofilms produced by four representative C. albicans strains (SC5314, CA22, CA37 and
CA688) were visualised under an inverted microscope (Olympus IMT-2) at 400× magnifica-
tion, following 24h exposure to the peptide.
Activity of hLF1-11 on pre-adhered C. albicans cells
C. albicans SC5314 (1×106 cells/mL) was suspended in diluted RPMI 1640 supplemented with
2% glucose and buffered with MOPS. Aliquots (100μL) of fungal suspension were inoculated
into 96-well plates, and incubated for 1.5h or 6h permitting fungal adhesion. In parallel, plates
were incubated for 24h to allow complete biofilm development, acting as a positive control.
Following incubation, non-adhered cells were removed by washing with sterile PBS, and
hLF1-11 (100μL) at various concentrations (44, 88 and 176mg/L) was added to each well.
Next, plates were further incubated for 24h at 37˚C for biofilm formation. Subsequently, evalu-
ation of biofilm cellular density, metabolic activity, and cell viability was carried out as previ-
ously described. Three independent experiments were performed, each in triplicate.
Quantitative real time RT-PCR (qRT-PCR) analysis of C. albicans
biofilm-related genes
qRT-PCR was used to investigate hLF1-11-induced changes in transcription level of genes
related to biofilm formation. Genes involved in the Ras1-cAMP-Efg1 pathway (RAS1, EFG1,
CYR1), MAP kinases pathway (HST7), Cph2-Tec1 pathway (TEC1), hyphal-specific genes
(ALS3, HWP1, ECE1), and genes related to the production of extracellular matrix (GSC1, ZAP1,
ADH5 and CSH1) were evaluated. C. albicans SC5314 cells (1×106 cells/mL) were grown in the
absence or presence of hLF1-11 (88 mg/L) in 24-well plates for 24 h at 37˚C. Next, wells were
washed with PBS and adhered cells were removed from the bottom of the wells by scraping (5
wells/sample). Total RNA was extracted from sessile cells with the Nucleospin RNA (Macherey
Nagel, Duren, Germany) according to manufacturer’s instructions and stored at -80˚C. The
quality and quantity of the extracted RNA were determined spectrophotometrically. Total
RNA (1μg) was converted into cDNA with random primers in a 20μL reaction volume, using
the Reverse Transcription System kit (Promega), following manufacturer’s instructions. Primer
sequences used for amplification of specific genes are shown in S1 Table. qRT-PCR mixtures
contained 6μL cDNA, 10μL SYBR Green Master Mix (Applied Biosystem, Life technologies,
Monza, Italy), 1pMol/μL of each primer, and sterile MilliQ water to a final volume of 20μL.
qRT-PCR was performed in a 96-well plates on CFX96 Touch Real-Time PCR Detection Sys-
tem (BioRad) (95˚C for 60s, followed by 40 cycles of 95˚C for 5s, 60˚C for 30s). Actin (ACT1)
was used as internal control. The transcription level of the selected genes was calculated using
the formula of 2-ΔΔCt. Three independent experiments were performed, each in triplicate.
cAMP rescue experiments
In order to verify the role of hLF1-11 in the inhibition of Ras1-cAMP-Efg1 pathway, the effect
of exogenous dibutyrylcAMP (db-cAMP; Sigma Aldrich, Milan Italy) on fungal cells treated
with the peptide was evaluated. Briefly, overnight C. albicans SC5314 cells (1×106 cells/mL)
were aliquoted into wells of a 24-well plate (1 mL/per well). A100 mM stock of db-cAMP solu-
tion was prepared in sterile water and stored at -20˚C. Db-cAMP was added to the fungal sus-
pension to a final concentration of 5mM, immediately following the addition of 44mg/L hLF1-
11. The untreated cells with or without db-cAMP served as control. Each sample was tested in
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triplicate. After incubation at 37˚C for 4h, cells were recovered (5,000×g for 5min) and visual-
ised (Olympus) at a 400× magnification. The percentage of cells growing as yeast, pseudohy-
phae and hyphae was determined from a mean of three replicate wells.
Statistical analysis
Data were expressed as means±standard error of the mean (S.E.M.). Results were evaluated by
one-way ANOVA test, followed by the Tukey-Kramer post-hoc test, using GraphPad Instat
software (version 6.05 for Windows, La Jolla, CA USA). The level of significance was set at a
P value of< 0.05.
Results
hLF1-11-induced candidacidal activity on planktonic cells
The hLF1-11-induced candidacidal activity on planktonic cells of ten clinical isolates and the
reference strain SC5314 was evaluated (Table 1). All strains exhibited similar susceptibility to
hLF1-11 with MIC values ranging from 22 to 44 mg/L (Table 1). No difference in hLF1-11
MIC values was found between fluconazole-resistant (CA688), and -susceptible clinical isolates
(Table 1).
hLF1-11 antibiofilm activity
The antibiofilm activity of hLF1-11 was evaluated against C. albicans reference strain SC5314
and on the clinical isolates (CA688, CA37, CA22) previously selected based on different RAPD
profiles (data not shown), propensity to produce biofilm (data not shown), and fluconazole
susceptibility (Table 1). Fungal cells were incubated in the absence and presence of different
peptide concentrations (44, 88 and 176mg/L). hLF1-11 induced a significant reduction in bio-
film cellular density, metabolic activity and number of viable cells, (P<0.05), in all the tested
strains (Fig 1). The antibiofilm activity was shown to occur in a dose-dependent manner. The
results revealed a 50% reduction in cellular density values after incubation with 44 mg/L hLF1-
11, compared to the untreated biofilm and a 100% reduction with doses higher than 88mg/L
(Fig 1a). Furthermore, a significant reduction in metabolic activity was observed in the pres-
ence of the peptide at 88 and 176mg/L (100%; P<0.05), compared to the untreated control
(Fig 1b), while no statistically significant reduction was observed at the lowest concentration
Table 1. MICs of fluconazole and hLF1-11 against planktonic cells of C. albicans clinical isolates and the reference strain SC5314.
Strain Source Fluconazole MIC (mg/L)a hLF1-11 MIC (mg/L)
SC5314 Reference strain 1 (S) 22
CA28 Blood culture 1 (S) 22
CA688 Bronchoalveolar lavage 64 (R) 22
CA22 Oral swab 1 (S) 22
CA5 Oral swab 1 (S) 44
CA31 Oral swab 1 (S) 44
CA37 Vaginal swab 1 (S) 44
CA3 Vaginal swab 1 (S) 22
CA17 Vaginal swab 1 (S) 22
CA18 Vaginal swab 1 (S) 44
CA35 Vaginal swab 1 (S) 22
aInterpretation of fluconazole susceptibility was performed according to the EUCAST (2015) clinical interpretive breakpoints:2mg/L Susceptible (S),
>4mg/L Resistant (R)
doi:10.1371/journal.pone.0167470.t001
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Fig 1. Effect of hLF1-11 on biofilm formation by four representative C. albicans strains. C. albicans cells (1x106 cells/
ml) were co-incubated with various concentrations of hLF1-11 for 24h at 37˚C. After incubation, the antibiofilm activity of the
peptide was assessed in terms of (a) biofilm cellular density reduction, (b) metabolic activity by the XTT assay, and c
reduction of sessile cell viability. Data are expressed as the mean of three independent experiments ± SEM. SC5314 open
bars, CA688 closed bars, CA22 dotted bars, CA37 diagonally hatched bars * P0.05, **P<0.01, ***P<0.001, as
compared to the untreated control biofilms.
doi:10.1371/journal.pone.0167470.g001
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(44mg/L). The hLF1-11 peptide also induced 1- and 2-log reduction in cell viability (CFU/mL)
at 88 and 176mg/L, respectively (Fig 1c). No decrease in cell viability was observed at the low-
est dose of hLF1-11 tested.
Kinetics of hLF1-11 antibiofilm activity
In order to assess whether the hLF1-11 antibiofilm activity after a 24-hour incubation could
also be observed at earlier stages, the peptide (88mg/L) and fungal cells were incubated for
1.5h, 3h, 6h and, as a control, 24h. Evaluation of early antibiofilm activity was performed con-
sidering the same parameters as previously described. Data obtained from kinetic experiments
demonstrated that hLF1-11 induced a reduction in biofilm formation after a 3h incubation
(Fig 2a and 2b). Interestingly, a complete abolishment of biofilm metabolic activity was
observed as early as 1.5h, which persisted up to 24h. In addition, hLF1-11 caused a 2-log reduc-
tion in sessile cell viability after a 3h incubation period, compared to untreated biofilms. This
reduction decreased to 1-log following a 24h incubation period.
hLF1-11 effect on C. albicans cell morphology
The hLF1-11 effect on biofilm architecture of the 4 C. albicans strains was evaluated using an
inverted microscope, following a 24h incubation in the presence/absence of the peptide. The
peptide induced a dose-dependent reduction in the number of hyphae compared to untreated
cells for all the strains tested (Fig 3a–3d). Indeed, microscopic observation in the absence of
the peptide revealed a very thick layer of mature biofilm, consisting of hyphae and matrix exo-
polysaccharide. In the presence of hLF1-11 at 44mg/L the biofilm layer appeared less compact
and homogeneous, with isolated hyphae. At higher concentrations (88 and 176mg/L), the pep-
tide completely inhibited biofilm formation, with fungal cells predominantly growing as yeast.
hLF1-11 effect on pre-adhered C. albicans cells
In order to evaluate whether the peptide could act on pre-adhered cells, cells were incubated
for 1.5 or 6h to allow adhesion to the 96-well plate or, as a control, 24h, prior to addition of dif-
ferent hLF1-11 concentrations (44, 88, and 176mg/L) and incubated for further 24h at 37˚C.
The results obtained indicate that the addition of hLF1-11 to C. albicans cells after 1.5h adhe-
sion induced a significant dose-dependent decrease in cellular density and metabolic activity
of the biofilm formed and about 1.5 log reduction (P<0.001) in colony count compared to the
control with the highest peptide concentration tested (176mg/L). Addition of hLF1-11 to cells
after a 6h adhesion phase revealed a significant decrease in biofilm cellular density at the con-
centrations of 88 and 176mg/L (Fig 4a), but no decrease in biofilm metabolic activity or in the
number of sessile viable cells at all the concentrations tested (Fig 4b and 4c). As expected, no
change was observed on preformed biofilm (Fig 4a–4c).
Transcriptional profiles of biofilm associated genes
The hLF1-11-induced changes at the transcriptional level of twelve genes related to biofilm
formation was assessed by qRT-PCR. The expression level of each gene was analysed in cells
exposed to the peptide (88mg/L) for 24h and compared to untreated cells (Fig 5). Analysis of
the actin-normalised data showed that the peptide induced a significant decrease in expression
level of the following genes: RAS1, CYR1, EFG1, ALS3, HWP1, ECE1,GSC1, ZAP1, and CSH1,
while hLF1-11 did not influence the expression of HST7, TEC1, and ADH5 genes. Further-
more, the latter showed a variable level of expression compared to the untreated control, in all
experimental replicates.
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Fig 2. Kinetics of hLF1-11 activity on biofilm formation by four representative C. albicans strains. C.
albicans SC5314 cells (1x106 cells/ml) were co-incubated with hLF1-11 (88mg/L) for different time periods
(1.5, 3, 6 and 24h) at 37˚C. Following incubation, the antibiofilm activity of the peptide was assessed in terms
of (a) biofilm cellular density reduction, (b) metabolic activity by the XTT assay, and (c) reduction of sessile cell
viability. Data are expressed as the mean of three independent experiments ± SEM. hLF1-11-treated sample
(square symbol), untreated sample (triangle symbol) ** P<0.01, ***P<0.001, as compared to the untreated
control biofilms.
doi:10.1371/journal.pone.0167470.g002
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Rescue of morphogenesis by exogenous cAMP
To verify the role of hLF1-11 in Ras1-cAMP-Efg1 pathway inhibition, exogenous db-cAMP
was administered to fungal cells immediately after treatment with the hLF1-11 peptide
(44mg/L) and microscopically evaluated after a 4h incubation. hLF1-11-treated cells used as a
control were mainly in the yeast form (Fig 6). db-cAMP addition to hLF1-11-treated cells
resulted in the recovery of filamentous growth. Fungal cell counts revealed a predominance of
cells in the yeast form (80%), with a few pseudohyphae (20%) and no hyphae in the hLF1-
11-treated sample, without exogenous db-cAMP. Notably, incubation with db-cAMP partially
restored morphogenesis, with a percentage of filamentous forms (pseudohyphae and hyphae)
rising to 60% (data not shown).
Discussion
The main finding from the present study demonstrates that hLF1-11 can significantly inhibit
C. albicans biofilm formation. This conclusion is based on the following findings. First, a
reduction of total cellular density, metabolic activity and cell viability was observed in a dose-
dependent manner after a 24-hour incubation. Second, kinetics experiments indicated that
Fig 3. Effect of hLF1-11 on biofilm architecture of C. albicans strains. Inverted microscope images (400×magnification) of (a) C.
albicans SC5314 and three clinical isolates, (b) CA688, (c) CA22, and (d) CA37, untreated and treated with 44mg/L, 88mg/L and
176mg/L hLF1-11. C. albicans strains were co-incubated with the different hLF1-11 concentrations at 37˚C for 24h.
doi:10.1371/journal.pone.0167470.g003
Inhibition of Candida albicans Biofilm by hLF1-11
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Fig 4. Effect of hLF1-11 on pre-adhered C. albicans cells. C. albicans SC5314 cells were allowed to adhere for different
times (1.5h, 6h and 24h) and then various concentrations of hLF1-11 were added and incubated for 24h at 37˚C. Following
incubation, the antibiofilm activity of the peptide was assessed in terms of (a) biofilm cellular density reduction, (b)
metabolic activity by the XTT assay, and (c) reduction of sessile cell viability. Data are expressed as the mean of three
independent experiments ± SEM. 1.5h closed bars, 6h open bars, 24h diagonally hatched bars * P0.05, **P<0.01,
***P<0.001, as compared to the untreated control biofilms.
doi:10.1371/journal.pone.0167470.g004
Inhibition of Candida albicans Biofilm by hLF1-11
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hLF1-11 inhibits early stages of biofilm formation in C. albicans, starting from 3h, where an
approximate 2-log reduction in sessile cell viability was observed, although a significant reduc-
tion of all biofilm parameters was shown after 6h.
However, the hLF1-11 inhibitory effect was only observed in biofilm cellular density in the
presence of pre-adhered cells (1.5-6h). Moreover, C. albicans mature biofilm was unaffected
following a 24h incubation with the peptide. Accordingly, other antimicrobial peptides, such
as β-peptides and LL37, exerted a direct antibiofilm activity on the first stages of C. albicans
biofilm formation [25–27].
Third, hLF1-11 inhibited C. albicans morphogenesis in a dose-dependent manner, in agree-
ment with previous results in vitro and in vivo [18].
In order to better understand the mechanisms underlying the observed antibiofilm effect of
hLF1-11 on C. albicans, we also investigated the transcriptional profiles of genes associated to
cell adhesion, hyphal growth and extracellular matrix production, under biofilm-inducing
conditions. The main signaling pathways involved in the induction of hyphae and biofilm for-
mation are the Ras1-cAMP-Efg1 and MAP kinase [5,28,29]. Interestingly, hLF1-11 signifi-
cantly decreased expression levels of RAS1, CYR1, EFG1, which are members of the Ras1-
cAMP-Efg1 pathway. Ras1 GTPase stimulates Cyr1 adenylate cyclase enzyme to synthesize
cAMP, which promotes activation of the Efg1 transcription factor. The latter plays an impor-
tant role in the regulation of some hypha-specific genes, such as ALS3, HWP1 and ECE1,
which are essential factors of C. albicans adhesion [30] as well as biofilm formation [29,31–33].
As expected, transcription of ALS3, HWP1 and ECE1 was also repressed. To confirm these
results, exogenous cAMP was added in order to evaluate whether hyphal growth could be
restored in hLF1-11-treated C. albicans cells. The results showed that db-cAMP could partially
restore C. albicans morphogenesis. This finding is in agreement with previous studies showing
an antibiofilm activity effect exerted via the inhibition of the Ras1-cAMP-Efg1 pathway
[34–36].
Fig 5. Quantitative real time RT-PCR analysis of C. albicans biofilm-related genes. C. albicans SC5314
biofilms were treated with 88mg/L of hLF1-11 in 24-well plates for 24h at 37˚C and the expression of the target
genes was determined qRT-PCR. Level of gene expression (closed column) is presented as fold change
relative to the control group (untreated biofilms, open column). ACT1 expression was used for normalization.
Assays were performed in triplicate and bars represent means ± S.E.M from three independent experiments.
** P<0.01 ***P<0.001.
doi:10.1371/journal.pone.0167470.g005
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In contrast, the hLF1-11 peptide did not affect transcriptional levels of HST7 and TEC1
genes. HST7 codifies a protein kinase belonging to the MAP kinase pathway, whereas TEC1
encodes a transcription factor that positively regulates the expression of hypha-specific genes,
independently from the two pathways described above [37]. On the other hand, C. albicans
morphogenesis is regulated by complex networks responding to a wide variety of extracellular
stimuli [38].
Although the composition of the extracellular matrix of C. albicans biofilm is still not
completely characterized, the presence of carbohydrates, proteins and nucleic acids has already
been described [39]. The main extracellular carbohydrate identified is β-1,3-glucan, synthe-
sized by the β-1,3-glucan synthase (Gsc1). For this reason, GSC1 transcript was included as an
index of the matrix production [40]. As expected, the hLF1-11 peptide down regulated GSC1
gene. Yet, little is known about the regulation of biofilm matrix production, which relies upon
complex regulatory mechanisms involving several transcription factors. C. albicans Zap1
(zinc-responsive activator protein) negatively regulated matrix production to promote cellular
dispersion. Zap1 directly activates the expression of CSH1 and IFD6, both of which inhibit
matrix accumulation, and indirectly represses the expression of other alcohol dehydrogenase
genes, such as ADH5, which promotes matrix production [41] We found that hLF1-11 reduced
transcript levels of ZAP1 and CSH1, whereas it did not influence the expression of ADH5. It is
worth noting that Zap1 is also required for efficient C. albicans morphogenesis, in agreement
Fig 6. Exogenous db-cAMP restored the hLF1-11-inhibited hyphal formation. A cell suspension of C. albicans SC5314 (1x106
cells/ml) was incubated at 37˚C with db-cAMP (5mM) immediately following the addition of 44mg/L hLF1-11. Peptide free cells with
or without db-cAMP served as control. After 4h, cells were recovered from the wells by centrifugation and visually inspected by
microscopy (400 ×magnification).
doi:10.1371/journal.pone.0167470.g006
Inhibition of Candida albicans Biofilm by hLF1-11
PLOS ONE | DOI:10.1371/journal.pone.0167470 November 30, 2016 12 / 15
with the finding that C. albicans ZAP1mutant mainly grows as yeast in biofilm (S1 Fig)
[41,42]. Consistently, microscopic examination revealed that hLF1-11-treated C. albicans cells
predominantly grew as yeast after a 24h incubation.
Overall, these results indicate that hLF1-11 inhibits early stages of biofilm formation in C.
albicans, by affecting yeast-hypha transition. In this regard, hLF1-11 seems to be a promising
candidate for a potential use as coating agent of prosthetic medical devices, as described for
other antimicrobial peptides [43,44].
Supporting Information
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